Research ExplorerPublicationsTreatment of AIDS-related lymphomas: rituximab is beneficial...

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.

Standard

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. / Wyen, Christoph; Jensen, Björn; Hentrich, Marcus; Siehl, Jan; Sabranski, Michael; Esser, Stefan; Gillor, Daniel; Müller, Markus; van Lunzen, Jan; Wolf, Timo; Bogner, Johannes R; Wasmuth, Jan C; Christ, Hildegard; Fätkenheuer, Gerd; Hoffmann, Christian.

In: AIDS, Vol. 26, No. 4, 4, 2012, p. 457-464.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wyen, C, Jensen, B, Hentrich, M, Siehl, J, Sabranski, M, Esser, S, Gillor, D, Müller, M, van Lunzen, J, Wolf, T, Bogner, JR, Wasmuth, JC, Christ, H, Fätkenheuer, G & Hoffmann, C 2012, 'Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.', AIDS, vol. 26, no. 4, 4, pp. 457-464. <http://www.ncbi.nlm.nih.gov/pubmed/22112600?dopt=Citation>

APA

Wyen, C., Jensen, B., Hentrich, M., Siehl, J., Sabranski, M., Esser, S., Gillor, D., Müller, M., van Lunzen, J., Wolf, T., Bogner, J. R., Wasmuth, J. C., Christ, H., Fätkenheuer, G., & Hoffmann, C. (2012). Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS, 26(4), 457-464. [4]. http://www.ncbi.nlm.nih.gov/pubmed/22112600?dopt=Citation

Vancouver

Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S et al. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS. 2012;26(4):457-464. 4.

Bibtex

@article{6a4333e1ac904be8aacce7a3c607356e,
title = "Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.",
abstract = "AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Cohort Studies, Prognosis, Follow-Up Studies, Disease-Free Survival, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Therapy, Combination, Germany/epidemiology, Tumor Markers, Biological/metabolism, Antineoplastic Agents/pharmacology/*therapeutic use, Acquired Immunodeficiency Syndrome/*drug therapy/immunology/mortality, Antibodies, Monoclonal, Murine-Derived/pharmacology/*therapeutic use, Antigens, CD20/*drug effects/metabolism, CD4-Positive T-Lymphocytes/*drug effects/metabolism, *Immunocompromised Host, Lymphoma, AIDS-Related/*drug therapy/immunology/mortality, Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Cohort Studies, Prognosis, Follow-Up Studies, Disease-Free Survival, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Therapy, Combination, Germany/epidemiology, Tumor Markers, Biological/metabolism, Antineoplastic Agents/pharmacology/*therapeutic use, Acquired Immunodeficiency Syndrome/*drug therapy/immunology/mortality, Antibodies, Monoclonal, Murine-Derived/pharmacology/*therapeutic use, Antigens, CD20/*drug effects/metabolism, CD4-Positive T-Lymphocytes/*drug effects/metabolism, *Immunocompromised Host, Lymphoma, AIDS-Related/*drug therapy/immunology/mortality",
author = "Christoph Wyen and Bj{\"o}rn Jensen and Marcus Hentrich and Jan Siehl and Michael Sabranski and Stefan Esser and Daniel Gillor and Markus M{\"u}ller and {van Lunzen}, Jan and Timo Wolf and Bogner, {Johannes R} and Wasmuth, {Jan C} and Hildegard Christ and Gerd F{\"a}tkenheuer and Christian Hoffmann",
year = "2012",
language = "English",
volume = "26",
pages = "457--464",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.

AU - Wyen, Christoph

AU - Jensen, Björn

AU - Hentrich, Marcus

AU - Siehl, Jan

AU - Sabranski, Michael

AU - Esser, Stefan

AU - Gillor, Daniel

AU - Müller, Markus

AU - van Lunzen, Jan

AU - Wolf, Timo

AU - Bogner, Johannes R

AU - Wasmuth, Jan C

AU - Christ, Hildegard

AU - Fätkenheuer, Gerd

AU - Hoffmann, Christian

PY - 2012

Y1 - 2012

N2 - AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.

AB - AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Cohort Studies

KW - Prognosis

KW - Follow-Up Studies

KW - Disease-Free Survival

KW - Antiretroviral Therapy, Highly Active

KW - CD4 Lymphocyte Count

KW - Drug Therapy, Combination

KW - Germany/epidemiology

KW - Tumor Markers, Biological/metabolism

KW - Antineoplastic Agents/pharmacology/therapeutic use

KW - Acquired Immunodeficiency Syndrome/drug therapy/immunology/mortality

KW - Antibodies, Monoclonal, Murine-Derived/pharmacology/therapeutic use

KW - Antigens, CD20/drug effects/metabolism

KW - CD4-Positive T-Lymphocytes/drug effects/metabolism

KW - Immunocompromised Host

KW - Lymphoma, AIDS-Related/drug therapy/immunology/mortality

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Cohort Studies

KW - Prognosis

KW - Follow-Up Studies

KW - Disease-Free Survival

KW - Antiretroviral Therapy, Highly Active

KW - CD4 Lymphocyte Count

KW - Drug Therapy, Combination

KW - Germany/epidemiology

KW - Tumor Markers, Biological/metabolism

KW - Antineoplastic Agents/pharmacology/therapeutic use

KW - Acquired Immunodeficiency Syndrome/drug therapy/immunology/mortality

KW - Antibodies, Monoclonal, Murine-Derived/pharmacology/therapeutic use

KW - Antigens, CD20/drug effects/metabolism

KW - CD4-Positive T-Lymphocytes/drug effects/metabolism

KW - Immunocompromised Host

KW - Lymphoma, AIDS-Related/drug therapy/immunology/mortality

M3 - SCORING: Journal article

VL - 26

SP - 457

EP - 464

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

M1 - 4

ER -